Results 341 to 350 of about 194,026 (392)

Proton Pump Inhibitors

Annals of Pharmacotherapy, 2016
Objective: The purpose of this article is to describe the relationship between proton pump inhibitors (PPIs) and symptoms of myopathy based on case reports. Data Sources: A literature search was conducted in PubMed (1946 to June 2016) using MeSH terms proton pump inhibitors, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole ...
Evan W, Colmenares, Ashley L, Pappas
  +6 more sources

Deprescribing proton pump inhibitors

Australian Journal of General Practice, 2022
Proton pump inhibitors (PPIs) are indicated for disorders including peptic ulcer disease and gastro-oesophageal reflux disease; however, they are often used for longer and at higher doses than recommended, or for indications that are not supported by evidence.The aim of this article is to outline evidence-based approaches to deprescribing PPIs.PPIs are
Turner, Justin P., Thompson, Wade, Reeve, Emily, Bell, J. Simon   +3 more
openaire   +4 more sources

Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication

Alimentary Pharmacology and Therapeutics, 2022
One‐week triple therapy with vonoprazan is endorsed by Japanese guidelines as an alternative to proton pump inhibitor (PPI)‐based triple therapy for first‐line Helicobacter pylori eradication.
D. Ang, S. Koo, Y. Chan, T. Tan, G. Soon, C. K. Tan, K. Lin, Jaydeesh‐Khanna Krishnasamy‐Balasubramanian, Y. Wong, Rahul Kumar, Rajesh R, Y. Tan, Peng Lan Jeannie Ong, Y. Tan, J. W. Li, A. Kwek, T. Ang   +16 more
semanticscholar   +1 more source

Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry

Alimentary Pharmacology and Therapeutics, 2020
Proton pump inhibitors (PPIs) are the most commonly used first‐line therapy for patients with eosinophilic oesophagitis (EoE). However, many aspects related to PPIs in EoE are still unknown.
E. Laserna-Mendieta, S. Casabona, D. Guagnozzi, E. Savarino, A. Perelló, A. Guardiola-Arévalo, J. Barrio, I. Pérez-Martínez, Anne Lund Krarup, J. Alcedo, S. de la Riva, Esther Rey-Iborra, C. Santander, Á. Arias, A. Lucendo   +14 more
semanticscholar   +1 more source

Endoscopic treatment of proton pump inhibitor‐refractory gastroesophageal reflux disease with anti‐reflux mucosectomy: Experience of 109 cases

Digestive Endoscopy, 2020
Some patients with gastroesophageal reflux disease (GERD) are refractory to proton pump inhibitor (PPI) therapy. Anti‐reflux mucosectomy (ARMS) is a minimally invasive endoscopic procedure for treatment of GERD.
K. Sumi, H. Inoue, Yasutoshi Kobayashi, Yugo Iwaya, Mary Raina Angeli Abad, Y. Fujiyoshi, Y. Shimamura, H. Ikeda, M. Onimaru   +8 more
semanticscholar   +1 more source

Potential proton pump inhibitor–related adverse effects

Annals of the New York Academy of Sciences, 2020
Proton pump inhibitors (PPIs) are one of the most common medications taken by patients worldwide. PPIs are used to treat acid‐related disorders, including gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori infection, and ...
I. E. Perry, I. Sonu, C. Scarpignato, J. Akiyama, M. Hongo, K. Vega   +5 more
semanticscholar   +1 more source

Proton pump inhibitors

Current Opinion in Gastroenterology, 2012
This review summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional deficiencies (B12 and magnesium), rebound acid hypersecretion, acute interstitial nephritis, gastric carcinoid tumor, cardiovascular risk with clopidogrel and PPI coprescription, bone fractures, enteric infections and pneumonia.
openaire   +3 more sources

Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction.

European Heart Journal, 2019
AIMS Guidelines differ in their recommendations on therapy to prevent gastrointestinal bleeding for patients treated with dual antiplatelet treatment (DAPT).
T. Sehested, N. Carlson, P. Hansen, T. Gerds, M. Charlot, C. Torp-Pedersen, L. Køber, G. Gislason, M. Hlatky, E. Fosbøl   +9 more
semanticscholar   +1 more source

Randomized trial of vonoprazan‐based versus proton‐pump inhibitor‐based third‐line triple therapy with sitafloxacin for Helicobacter pylori

Journal of Gastroenterology and Hepatology, 2018
This was a prospective, randomized trial of the efficacy of vonoprazan‐based and proton‐pump inhibitor‐based 7‐day triple regimens with amoxicillin and sitafloxacin as a third‐line therapy for eradicating Helicobacter pylori after failure of ...
Soichiro Sue, W. Shibata, Tomohiko Sasaki, H. Kaneko, K. Irie, M. Kondo, S. Maeda   +6 more
semanticscholar   +1 more source

Proton Pump Inhibitors

Reactions Weekly, 2017
Guidelines generally recommend proton pump inhibitors (PPIs) over histamine type 2 receptor antagonists when acid suppression is advocated because of a longer duration of action, a superior ability in reducing acid secretion, and the absence of tachyphylaxis with repeated dosing.
Licia Pensabene, Geoffrey Davidson
openaire   +2 more sources